The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials

The 12-mo castration efficacy rate and adverse event (AE) rate of oral gonadotropin-releasing hormone (GnRH) antagonists are comparable with those of parenteral GnRH antagonists and superior to those of GnRH agonists, except for the 3-mo formulation of degarelix (480 mg). Relugolix is a promising GnRH antagonist to overcome the injection site reaction that is the main usage barrier of degarelix. However, until longer follow-up results are obtained, we have to be cautious regarding the wide clinical use of relugolix and its serious adverse events.